Breast Cancer, Fatigue Related to Cancer Treatment
Conditions
Keywords
Nuvastatic, Breast Cancer, Cancer related fatigue, Randomized double blind placebo controlled trail, First-Line Chemotherapy
Brief summary
The goal of this clinical trial is to evaluate whether Nuvastatic 300 mg capsules can reduce cancer-related fatigue in adult patients with colon cancer undergoing first-line chemotherapy. The main questions it aims to answer are: * Does Nuvastatic 300 mg capsules significantly reduce cancer-related fatigue compared to placebo? * Is Nuvastatic 300 mg capsules safe and well tolerated in this patient population? Researchers will compare Nuvastatic 300 mg capsules vs placebo to see if Nuvastatic 300 capsule improves fatigue scores and maintains an acceptable safety profile. Participants will: * Receive Nuvastatic 300 mg capsules or placebo capsules (3 times per day) for 3 cycles of 20 days each (total \ 60 treatment days). * Continue their standard first-line chemotherapy regimen. * Provide blood sample assessments at Screening and End of Treatment. * Complete patient diaries and fatigue assessments as per protocol.
Interventions
DRUGNuvastatic 300
300mg capsule, (3 capsules X 3 times a day)
DRUGPlacebo
300mg capsule, (3 capsules X 3 times a day)
Sponsors
Natureceuticals Sdn Bhd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Investigator)
Masking description
Details of the investigational product (Nuvastatic or placebo) are concealed from both the study investigators and the trial participants. Each enrolled subject receives a randomization code allocated sequentially through IWRS.
Intervention model description
Randomized, Double-blind, Placebo-controlled, Parallel-group study
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Female patients aged ≥ 18 years and ≤ 65 years who are willing to voluntarily provide consent for participation in the study. * Patients with confirmed triple negative metastatic breast cancer who are planned or scheduled to receive standard chemotherapy treatment for at least 4 to 6 cycles respectively. * Patients must have a confirmed diagnosis of triple negative metastatic breast cancer as per standard guidelines. * Patients must have at least one tumour lesion with ≥ 1cm in one dimension that is radiographically apparent on computed tomography (CT) or magnetic resonance imaging (MRI). * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at screening. * The patient has stable haemoglobin (≥ 9 g/dL) throughout the screening. * Life expectancy ≥ 6 months, as per the investigator's judgment. * Patients with co-morbidities or medical conditions including Type 2 diabetes mellitus (DM) and hypertension who are deemed stable by the investigator can be included in the study. * At screening, patients with stable fatigue, newly developed fatigue, or worsening fatigue scores as assessed by the Brief Fatigue Inventory (BFI) should be included.
Exclusion criteria
* Patients who have any untreated reversible medical condition which may cause fatigue (e.g. major metabolic or electrolyte disturbance, active infection, endocrine abnormalities) as per the investigator's clinical judgment. * Patients with an inability to understand local language(s) for scales used for evaluations i.e. VAFS, BFI AND SF-36. * Patients who have received concurrent stimulant medication (e.g. dextroamphetamine or methylphenidate) during the screening period or any medication which may interfere with the study drug. * Patients with any delay in chemotherapy treatment such that the screening period extends beyond 21 days. * Patients with known central nervous system (CNS) involvement. * Patients with any serious, uncontrolled, non-malignant medical or psychiatric disorder, or any other medical condition which in the opinion of the investigator, may affect the patient's safety or study participation and conduct. * Female patients who are pregnant or breastfeeding. * Patients with known hepatitis C virus, hepatitis B virus, HIV infection. * Patients who have nausea and vomiting or any gastrointestinal disorder that is severe enough to interfere with study drug absorption in the opinion of the investigator. * Patients with uncontrolled pain, who in the opinion of the investigator are not eligible for the study. * Patients with known hypersensitivity or intolerance of rosmarinic acid, caffeic acid, and other related phenolic compounds as well as excipients in the Nuvastatic® 300 mg or placebo treatment. * Patients with planned therapy or treatment with another investigational agent. * Previous exposure to any investigational agent within 4 weeks prior to screening, or planned administration of an investigational agent, other than as specified by this protocol, during the study period.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Reduction in cancer-related fatigue in breast cancer patients undergoing first-line chemotherapy, assessed after treatment with Nuvastatic versus placebo. | From Screening to EOT (about 6 months) | The primary outcome measure is the intra-individual changes in the Brief Fatigue Inventory (BFI) fatigue scale. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall QoL and functional improvement | at baseline and at end of the study (about 6 months) | The secondary outcome measure is the overall QoL improvement using the medical outcome scale Short Form-36 (SF-36). |
| Reduction in cancer-related fatigue in breast cancer patients undergoing first-line chemotherapy, assessed after treatment with Nuvastatic versus placebo. | From Screening to EOT (about 6 months) | The primary outcome measure is the intra-individual changes in the Visual Analogue Fatigue Scale (VAFS). |
Countries
India
Contacts
CONTACTAman Shah Abdul Majid, MBChB, DPhil
Outcome results
None listed